All lobbying filings
STEALTH BIOTHERAPEUTICS INC.
Lobbying for STEALTH BIOTHERAPEUTICS INC. · Developing therapies to treat mitochondrial dysfunction.
Filing · LD-2 quarterly report
Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Expenses
$50,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Massachusetts
Government bodies contacted
2
Lobbying activity
1
H.R. 7384/S. 4583, the Creating Hope Reauthorization Act of 2024 (118th Congress) H.R. 1509/S. 752 the Accelerating Kids Access to Care Act H.R. 1262/S. 932 - Give Kids a Chance Act of 2025 General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings H.R. 1092/S. 526, the BENEFIT Act (118th Congress) General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025 General discussions about ultra-rare diseases FDA Rare Disease Innovation Hub